Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 17/20 | 0.80 |
| ▸ | DPP7 | Q9UHL4 | 3/20 | 0.80 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.80 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL220478 | 0.89 | DPP4 (1.00) | DPP4DPP7DPP8 | |
| SCHEMBL29416829 | 0.89 | DPP4 (1.00) | DPP4DPP7DPP8 | |
| SCHEMBL160102 | 0.89 | DPP4 (1.00) | DPP4DPP7DPP8 | |
| Hydrochloric Acid SCHEMBL299895 | 0.88 | DPP4 (0.98) | DPP4DPP7DPP8 | |
| Hydrochloric Acid SCHEMBL356224 | 0.88 | DPP4 (0.98) | DPP4DPP7DPP8 | |
| Hydrochloric Acid SCHEMBL356225 | 0.88 | DPP4 (0.98) | DPP4DPP7DPP8 | |
| SCHEMBL8245189 | 0.87 | DPP4 (0.85) | DPP4DPP7DPP8 | |
| Hydrochloric Acid SCHEMBL1069087 | 0.83 | DPP4 (0.86) | DPP4DPP7DPP8 | |
| Hydrochloric Acid SCHEMBL1069089 | 0.83 | DPP4 (0.86) | DPP4DPP7DPP8 | |
| SCHEMBL5489225 | 0.82 | DPP4 (0.74) | DPP4DPP7DPP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120294939-A1 | DIRECT COMPRESSION FORMULATION AND PROCESS | KOWALSKI JAMES (US) | 2012-11-22 | — | — | US | disclosed |
| US-20120015029-A1 | DIRECT COMPRESSION FORMULATION AND PROCESS | PFEFFER SABINE (DE) | 2012-01-19 | — | — | US | disclosed |
| US-7935723-B2 | Metformin and a dipeptidyl peptidase IV inhibitor such as vildagliptin; improving glucose control | NOVARTIS PHARMA AG (CH) | 2011-05-03 | — | — | US | disclosed |
| US-20100160408-A1 | VILDAGLIPTIN FOR TREATING GENERAL PERIPHERAL NEUROPATHIES | NOVARTIS AG (CH) | 2010-06-24 | — | — | US | disclosed |
| US-20090253752-A1 | COMBINATION OF DPP-IV INHIBITOR, PPAR ANTIDIABETIC AND METMORFIN | BURKEY BRYAN | 2009-10-08 | — | — | US | disclosed |
| US-20090143469-A1 | SALTS OF NATEGLINIDE | SUTTON PAUL ALLEN | 2009-06-04 | — | — | US | disclosed |
| US-20090054512-A1 | USE OF ORGANIC COMPOUNDS | FOLEY JAMES E | 2009-02-26 | — | — | US | disclosed |
| US-20080299190-A1 | Direct Compression Formulation and Process | NOVARTIS AG (CH) | 2008-12-04 | — | — | US | disclosed |
| US-20080300293-A1 | COMBINATION OF AN DPP-IV INHIBITOR AND A PPAR-ALPHA COMPOUND | WANG PEI-RAN | 2008-12-04 | — | — | US | disclosed |
| EP-1419173-B1 | PEPTIDES THAT BIND TO ATHEROSCLEROTIC LESIONS | NOVARTIS AG (CH) | 2008-11-26 | — | — | EP | disclosed |
| US-20080227825-A1 | Dipeptidylpeptidase IV inhibitors such as vildagliptin and metformin; tablets | JOSHI YATINDRA | 2008-09-18 | — | — | US | disclosed |
| US-20080221200-A1 | Combination of Organic Compounds | ALLISON MALCOLM | 2008-09-11 | — | — | US | disclosed |
| US-20080200510-A1 | Combination of Organic Compounds | MILOSAVLJEVIC-RISTIC SMILJANA | 2008-08-21 | — | — | US | disclosed |
| US-20080193529-A1 | Direct Compression Formulation and Process | KOWALSKI JAMES | 2008-08-14 | — | — | US | disclosed |
| US-20080038341-A1 | Free-flowing, cohesive tableting powder for direct compressed tablet; DPP-IV inhibitor and glitazone, in unit dosage form; acceptable dissolution profile; acceptable degrees of hardness, resistance to chipping, short disintegration time | KOWALSKI JAMES | 2008-02-14 | — | — | US | disclosed |
| US-20070264194-A1 | Peptides That Bind To Atherosclerotic Lesions | THE SCRIPPS RESEARCH INSTITUTE (US) | 2007-11-15 | — | — | US | disclosed |
| US-20070254944-A1 | Use of Organic Compounds | NOVARTIS AG (CH) | 2007-11-01 | — | — | US | disclosed |
| US-20070149451-A1 | Combination of a dpp IV inhibitor and an antiobesity or appetite regulating agent | HOLMES DAVID G | 2007-06-28 | — | — | US | disclosed |
| US-20070027197-A1 | Pharmaceutical composition and method for the treatment of diseases using HMG-CoA reductase inhibitors and insulin secretion enhancers or sensitizers | DAMON ROBERT E | 2007-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (17 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080299190-A1 | Direct Compression Formulation and Process | DPP4, DPP3, DPP7 | DPP4 1/4885DPP7 3/4885DPP8 6/4885 |
| US-20070149451-A1 | Combination of a dpp IV inhibitor and an antiobesity or appetite regulating agent | GIPR, DPP4, MC4R | DPP4 2/4885DPP7 9/4885DPP8 20/4885 |
| US-20080038341-A1 | Free-flowing, cohesive tableting powder for direct compressed tablet; DPP-IV inhibitor and glitazone, in unit dosage form; acceptable dissolution profile; acceptable degrees of hardness, resistance to chipping, short disintegration time | DPP4, DPP3, DPP7 | DPP4 1/4885DPP7 3/4885DPP8 4/4885 |
| US-20120015029-A1 | DIRECT COMPRESSION FORMULATION AND PROCESS | DPP4, DPP3, DPP7 | DPP4 1/4885DPP7 3/4885DPP8 6/4885 |
| US-20090143469-A1 | SALTS OF NATEGLINIDE | AREG, AGT, TGFB1 | DPP4 290/4885DPP7 367/4885DPP8 695/4885 |
| US-20080300293-A1 | COMBINATION OF AN DPP-IV INHIBITOR AND A PPAR-ALPHA COMPOUND | PPARG, DPP4, FABP4 | DPP4 2/4885DPP7 18/4885DPP8 17/4885 |
| US-20070264194-A1 | Peptides That Bind To Atherosclerotic Lesions | FABP3, CCL2, VCAM1 | DPP4 659/4885DPP7 651/4885DPP8 1189/4885 |
| US-20080200510-A1 | Combination of Organic Compounds | DPP4, DPP3, DPP9 | DPP4 1/4885DPP7 5/4885DPP8 4/4885 |
| US-20090253752-A1 | COMBINATION OF DPP-IV INHIBITOR, PPAR ANTIDIABETIC AND METMORFIN | PPARG, DPP4, DPP3 | DPP4 2/4885DPP7 5/4885DPP8 7/4885 |
| US-20080193529-A1 | Direct Compression Formulation and Process | DPP4, DPP3, DPP7 | DPP4 1/4885DPP7 3/4885DPP8 4/4885 |
| US-20070027197-A1 | Pharmaceutical composition and method for the treatment of diseases using HMG-CoA reductase inhibitors and insulin secretion enhancers or sensitizers | HMGCR, PCSK9, INSR | DPP4 632/4885DPP7 606/4885DPP8 808/4885 |
| US-20080221200-A1 | Combination of Organic Compounds | DPP4, DPP3, DPP7 | DPP4 1/4885DPP7 3/4885DPP8 5/4885 |
| US-20100160408-A1 | VILDAGLIPTIN FOR TREATING GENERAL PERIPHERAL NEUROPATHIES | DPP4, DPP3, DPP7 | DPP4 1/4885DPP7 3/4885DPP8 5/4885 |
| US-20080227825-A1 | Dipeptidylpeptidase IV inhibitors such as vildagliptin and metformin; tablets | DPP4, DPP3, DPP7 | DPP4 1/4885DPP7 3/4885DPP8 4/4885 |
| US-20070254944-A1 | Use of Organic Compounds | DPP4, DPP8, DPP3 | DPP4 1/4885DPP7 4/4885DPP8 2/4885 |
| US-20090054512-A1 | USE OF ORGANIC COMPOUNDS | DPP4, DPP3, DPP7 | DPP4 1/4885DPP7 3/4885DPP8 4/4885 |
| US-20120294939-A1 | DIRECT COMPRESSION FORMULATION AND PROCESS | DPP4, DPP3, DPP7 | DPP4 1/4885DPP7 3/4885DPP8 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.